Santen Pharmaceutical Co., Ltd. (4536.T)

1,491.50 -13.50 (-0.90%) At close: 03:15PM JST

Santen Pharmaceutical Co., Ltd.

Grand Front Osaka Tower A
4-20 Ofuka-cho Kita-ku
Osaka 530-8552
Japan
81 6 7664 8621
https://www.santen.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 4,144

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Takeshi Ito	President, CEO & Representative Director	N/A	N/A	1959
Mr. Kazuo Koshiji	Chief Financial Officer & Chief Risk Officer	N/A	N/A	N/A
Ms. Rie Nakajima	COO & Corporate Officer	N/A	N/A	N/A
Mr. Minori Hara	Chief Digital & Information Officer	N/A	N/A	N/A
Ms. Kaori Itagaki	General Manager of Investor Relations Group	N/A	N/A	N/A
Ms. Mika Masunari	General Counsel & Chief Compliance Officer	N/A	N/A	N/A
Ms. Nobuko Kato	Chief Communications Officer	N/A	N/A	N/A
Mr. Satoshi Suzuki	Senior Corporate Officer & Head of Corporate Development Division & Director	N/A	N/A	1963
Mr. Shinichi Teramachi	Corporate Officer, Head of Sales Department & Japan Sales and Marketing Division	N/A	N/A	N/A
Mr. Ippei Kurihara	Corporate Officer and Head of Marketing Department, Japan Business, Japan Sales & Marketing Division	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.

Corporate governance

Santen Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.